NCT03171142

Effect of Heliox on RSV Bronchiolitis

Effect of Heliox on Infants With Respiratory Syncytial Virus Acute Bronchiolitis-A Revisit Study

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 104 (actual)
• Sponsor: Wael Seliem · Academic / Other
• Sex: All
• Age: 1 Month – 2 Years
• Healthy volunteers: Not accepted

Summary

Helium is an inert gas with a density almost one-seventh of that of air. Based on its properties breathing a mixture of helium and oxygen (heliox) will lead to a reduction in resistance through narrowed airways and consequently decreases the work of breathing. Participating infants with RSV acute bronchiolitis will be supplied with heliox (ration of 21 oxygen and 79 helium) delivered through a flow nasal cannula to evaluate heliox effect in improving their oxygenation. Heliox will act as an additive therapy to improve oxygenation in patients with lower respiratory tract infection caused by respiratory Syncytial Virus (RSV) and will decrease the need for more complicated therapies.

Conditions

• RSV Infection
• Acute Bronchiolitis

Interventions

Type	Name	Description
DRUG	Heliox	Heliox (21:79) via nasal cannula 2 litter per minutes
DRUG	Air	Air 21% via nasal cannula 2 litter per minutes

Timeline

• Start date: 2015-05-01
• Primary completion: 2016-08-01
• Completion: 2017-05-01
• First posted: 2017-05-31
• Last updated: 2017-05-31